Leqembi Facing 15% Price Cut In Japan

Outcome Of CEA Process

 
• By Lisa Takagi
  
CEA discussion on Leqembi
Eisai's Alzheimer's drug Leqembi appears set for 15% price cut in Japan following cost-effectiveness review. (Shutterstock/AI-generated)

More from Health Technology Assessment

More from Japan